(2026). Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: Mechanisms, current trends and challenge for clinical translation. PeerJ.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Cardiovascular, and Cerebrovascular Diseases: Mechanisms, Current Trends and Challenge for Clinical Translation."
PeerJ 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Cardiovascular, and Cerebrovascular Diseases: Mechanisms, Current Trends and Challenge for Clinical Translation."
PeerJ, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.